Citizens downgrades Option Care Health stock rating on McKesson deal
Citizens downgraded Option Care Health (OPCH) to Market Perform from Market Outperform after its acquisition by McKesson (MCK) and CD&R for $32.05 per share, a 37% premium. The deal values the company at $5.8B. OPCH's Q2 earnings beat expectations, with $0.45 EPS and $1.44B revenue. Analysts have mixed views on the stock.
How this was made
The 30-second read
Why it matters
The downgrade may trigger immediate sell pressure on OPCH, while the strategic stake for MCK could be viewed positively, creating divergent short‑term price dynamics.
Market read
Primary M&A news with a sizable transaction and analyst downgrade provides actionable trading signals for both OPCH and MCK.
What to watch
Potential regulatory scrutiny of the joint ownership structure and the impact on Option Care's existing contracts.
Background
Citizens' downgrade follows the announcement of a cash acquisition of Option Care Health by McKesson and private equity firm CD&R, with a 37% premium to the recent closing price.
Ticker impact
Citizens downgraded Option Care Health to Market Perform after announcing a $5.8 B cash acquisition by McKesson and CD&R at $32.05 per share.
likely downward pressure as investors price in the downgrade and integration risk
Analyst downgrade combined with a large cash deal often leads to a near‑term pullback, even though the premium is sizable.
McKesson agreed to acquire a 49% stake in Option Care Health for $32.05 per share in a $5.8 B transaction.
moderate upside as the market views the acquisition as strategic growth
Strategic stake acquisition may be viewed favorably, but the size of the deal relative to McKesson's market cap tempers the move.
Market effects
Consolidation in the home‑infusion and specialty pharmacy sector could pressure peers.
U.S. healthcare services sector may see modest re‑rating as the deal signals further M&A activity.
Limited to U.S. healthcare market; no broader macro impact.
Counterpoint
The premium may be over‑valued; integration risk could outweigh growth benefits, suggesting a short position.
Key entities
- CompanyOption Care Health
Home infusion services provider being acquired.
- CompanyMcKesson
Pharmaceutical distributor acquiring a 49% stake.
- Research FirmCitizens
Analyst house that downgraded OPCH.
